Van de Mierop L, Rutgeerts L, Van den Langenbergh B, Staessen A
Digestion. 1979;19(4):244-50. doi: 10.1159/000198352.
32 patients with chronic postprandial dyspepsia were selected for a 4-week controlled double-blind trial of domperidone and a placebo. The patients received either domperidone or a placebo at a dose rate of two 10-mg tablets t.i.d. before meals. A questionnaire was completed at the start of the study, and after 2 and 4 weeks of treatment. Excellent or good improvement was obtained in 71% of the domperidone-treated patients compared to only 13% of the placebo-treated cases. Domperidone was also significantly superior to the placebo when both drugs were compared to previously used medications. Side effects were not reported. It is concluded that domperidone has a beneficial effect on chronic postprandial dyspepsia.
32例慢性餐后消化不良患者被选入一项为期4周的多潘立酮与安慰剂对照双盲试验。患者在饭前以每日三次、每次两片10毫克片剂的剂量服用多潘立酮或安慰剂。在研究开始时以及治疗2周和4周后完成一份问卷。多潘立酮治疗的患者中有71%获得了优或良的改善，而安慰剂治疗的病例中只有13%。与先前使用的药物相比，两种药物比较时多潘立酮也显著优于安慰剂。未报告有副作用。结论是多潘立酮对慢性餐后消化不良有有益作用。
